1. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008; 358:2606-2617.

2. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML, ed. Handbook of Experimental Pharmacology. Vol 69. Berlin: Springer Verlag, 1984:16-119.

3. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol 1993; 37:435-456.

4. Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev 2006; 58:1164-1181.

5. Del Amo E, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008; 13:135-143.

6. Järvinen K, Järvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev 1995; 16:3-19.

7. Huang HS, Schoenwald RD, Lach JL. Corneal penetration behavior of beta blockers. J Pharm Sci 1983; 72:1272-1279.

8. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58:1131-1135.

9. Conrad JM, Robinson JR. Aqueous chamber drug distribution volume measurement in rabbits. J Pharm Sci 1977; 66:219-224.

10. Miller SC, Gokhale RD, Patton TF, et al. Pilocarpine ocular distribution volume. J Pharm Sci 1980; 69:615-616.

11. Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci 1985; 26:584-587.

12. Lee SB, Geroski DH, Prausnitz MR, et al. Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res 2004; 78:599-607.

13. Charles NC, Steiner GC. Ganciclovir intraocular implant. A clinicopathologic study. Ophthalmology 1996; 103:416-421.

14. Lee VH, Carson LW, Kashi SD, et al. Metabolic and permeation barriers to the ocular absorption of topically applied enkephalins in albino rabbits. J Ocul Pharmacol 1986; 2:345-352.

15. Hamalainen KM, Kananen K, Auriola S, et al. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 1997; 38:627-634.

16. Hamalainen KM, Ranta VP, Auriola S, et al. Enzymatic and permeation barrier of [D-Ala(2)]-Met-enkephalinamide in the anterior membranes of the albino rabbit eye. Eur J Pharm Sci 2000; 9(3):265-270.

17. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci 1995; 36:1893-1903.

18. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 2000; 41:1181-1185.

19. Chiang TH, Walt JG, McMahon JP Jr., et al. Real-world utilization patterns of cyclosporine ophthalmic emulsion 0.05% within managed care. Can J Clin Pharmacol 2007; 14:e240-e245.

20. Kim H, Lizak MJ, Tansey G, et al. Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann Biomed Eng 2005; 33:150-164.

21. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 112:2179-2182.

22. Pitkanen L, Pelkonen J, Ruponen M, et al. Neural retina limits the non-viral gene transfer to RPE in an in vitro bovine eye model. AAPS J 2004; 6(3):e25.

23. Pitkanen L, Ranta VP, Moilanen H, et al. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci 2005; 46:641-646.

24. Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications, Adv Drug Deliv Rev 2006; 58:1182-1202.

25. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003; 44:3562-3569.

26. Peng S, Rahner C, Rizzolo LJ. Apical and basal regulation of the permeability of the retinal pigment epithelium. Invest Ophthalmol Vis Sci 2003; 44:808-817.

27. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 1998; 87:1479-1488.

28. Bill A. Capillary permeability to and extravascular dynamics of myoglobin, albumin and gammaglobulin in the uvea. Acta Physiol Scand 1968; 73:204-219.

29. Li H, Tran VV, Hu Y, et al. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp Eye Res 2006; 83:824-833.

30. Halhal M, Renard G, Courtois Y, et al. Iontophoresis: from the lab to the bed side. Exp Eye Res 2004; 78:751-757.

31. Eljarrat-Binstock E, Orucov F, Aldouby Y, et al. Charged nanoparticles delivery to the eye using hydrogel iontophoresis. J Control Release 2008; 126:156-161.

32. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358:2231-2239.

33. Toropainen E, Hornof M, Kaarniranta K, et al. Corneal epithelium as a platform for secretion of transgene products after transfection with liposomal gene eyedrops. J Gene Med 2007; 9(3):208-216.

34. Bush RA, Lei B, Tao W, et al. Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology. Invest Ophthalmol Vis Sci 2004; 45:2420-2430.

35. Tao W. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 2006; 6:717-726.

36. Wikström J, Syvajarvi H, Urtti A, et al. Kinetic simulation model of protein secretion and accumulation in the cell microcapsules. J Gene Med 2008; 10:575-582.

37. Wikstrom J, Elomaa M, Syvajarvi H, et al. Alginate based microencapsulation of retinal pigment epithelial cell line for cell Therapy. Biomaterials 2008; 29:869-876.

0 0

Post a comment